AMPKα, hs-CRP and FcγR in diabetic nephropathy and drug intervention

Sun,Ping; Lu,Lei; Chen,Jun; Liu,Xiao Dan; Zhang,Qing; Wang,Xu

doi:10.3892/etm.2018.6034

AMPKα, hs-CRP and FcγR in diabetic nephropathy and drug intervention

Authors:
- Ping Sun
- Lei Lu
- Jun Chen
- Xiao Dan Liu
- Qing Zhang
- Xu Wang
View Affiliations

Affiliations: The First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China, Xuzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Xuzhou, Jiangsu 221003, P.R. China
Published online on: April 4, 2018 https://doi.org/10.3892/etm.2018.6034
Pages: 4659-4664
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the roles of AMP-activated protein kinase α subunit (AMPKα), hypersensitive C-reactive protein (hs-CRP) and Fcγ receptor (FcγR) in diabetic nephropathy and drug intervention effects. Sixty Sprague Dawley male rats were randomly divided into the control (n=30) and observation (n=30) groups. The model of type 2 diabetic nephropathy was established by high-fat and high-glucose diet and streptozotocin injection. The rats in the observation group were treated with baicalein and the rats in control group did not receive any drug intervention. The pathological changes of kidneys were observed by hematoxylin and eosin (H&E) staining. The expression of AMPKα mRNA in renal tissue was detected by reverse transcription-polymerase chain reaction (RT-PCR). The levels of hs-CRP and FcγR were measured by enzyme‑linked immunosorbent assay (ELISA) at 1, 4, 6 and 8 weeks after drug intervention and blood urea nitrogen (BUN) and the 24 h urinary micro-albumin (U-ALB) levels were compared at 1, 4, 6 and 8 weeks after intervention. After 8 weeks of drug intervention, the pathological changes of kidneys in the observation group were significantly lower than those in the control group (p<0.05), while the relative expression levels of AMPKα mRNA and protein in the control group were higher than those in the observation group (p<0.05). The levels of hs-CRP, BUN and 24 h U-ALB in the control group were significantly higher than those in the observation group at different time-points after drug intervention and the level of FcγR in the control group was significantly lower than that in the observation group (p<0.05). Baicalein may protect renal function by inhibiting the expression of AMPKα and inflammatory reaction, and can also decrease BUN and 24 h U-ALB levels and improve the pathological changes of the kidney.

View Figures

View References

1	d'Emden MC, Shaw JE, Jones GR and Cheung NW: Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus. Med J Aust. 203:89–90. 2015. View Article : Google Scholar : PubMed/NCBI
2	Mellitus D and Glucose O: American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 36 Suppl 1:S67–S74. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tsai SF, Su CW, Wu MJ, Chen CH, Fu CP, Liu CS and Hsieh M: Urinary Cyclophilin A as a new marker for diabetic nephropathy: A cross-sectional analysis of diabetes mellitus. Medicine (Baltimore). 94:e18022015. View Article : Google Scholar : PubMed/NCBI
4	Cooper ME, Gilbert RE and Epstein M: Pathophysiology of diabetic nephropathy. Metabolism. 47 Suppl 1:3–6. 1998. View Article : Google Scholar : PubMed/NCBI
5	Maezawa Y, Takemoto M and Yokote K: Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 6:3–15. 2015. View Article : Google Scholar : PubMed/NCBI
6	Pineda CT, Ramanathan S, Tacer Fon K, Weon JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015. View Article : Google Scholar : PubMed/NCBI
7	Liao L, Lei MX, Chen HL, Wu J and Guo LJ: High-sensitive C-reactive protein and Type 2 diabetic nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 29:627–630. 2004.(In Chinese). PubMed/NCBI
8	Nimmerjahn F, Gordan S and Lux A: FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 36:325–336. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ahmad J: Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab Syndr. 9:343–358. 2015. View Article : Google Scholar : PubMed/NCBI
10	Bangstad HJ, Osterby R, Rudberg S, Hartmann A, Brabrand K and Hanssen KF: Kidney function and glomerulopathy over 8 years in young patients with Type I (insulin-dependent) diabetesmellitus and microalbuminuria. Diabetologia. 45:253–261. 2002. View Article : Google Scholar : PubMed/NCBI
11	Rigalleau V, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, Chauveau P, Combe C and Gin H: Glucose control influencesglomerular filtration rate and its prediction in diabetic subjects. Diabetes Care. 29:1491–1495. 2006. View Article : Google Scholar : PubMed/NCBI
12	Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, Kimura K, Suzuki Y, Wada T, Ogawa S, et al: A new classification of Diabetic Nephropathy 2014: A report from Joint Committee on Diabetic Nephropathy. Clin Exp Nephrol. 19:1–5. 2015. View Article : Google Scholar : PubMed/NCBI
13	Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B and Jones RG: Differential effects of AMPK agonists on cell growth and metabolism. Oncogene. 34:3627–3639. 2015. View Article : Google Scholar : PubMed/NCBI
14	Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, Yurchenko E, Raissi TC, van der Windt GJ, Viollet B, Pearce EL, et al: The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 42:41–54. 2015. View Article : Google Scholar : PubMed/NCBI
15	Ford RJ, Fullerton MD, Pinkosky SL, Day EA, Scott JW, Oakhill JS, Bujak AL, Smith BK, Crane JD, Blümer RM, et al: Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J. 468:125–132. 2015. View Article : Google Scholar : PubMed/NCBI
16	Shimoda M, Kaneto H, Yoshioka H, Okauchi S, Hirukawa H, Kimura T, Kanda-Kimura Y, Kohara K, Kamei S, Kawasaki F, et al: Influence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence between in obese and non-obese subjects. J Diabetes Investig. 7:197–205. 2015. View Article : Google Scholar : PubMed/NCBI
17	Varma V, Varma M, Varma A, Kumar R, Bharosay A and Vyas S: Serum total sialic acid and highly sensitive C-reactive protein: Prognostic markers for the diabetic nephropathy. J Lab Physicians. 8:25–29. 2016. View Article : Google Scholar : PubMed/NCBI
18	Alam F, Fatima F, Orakzai S, Iqbal N and Fatima SS: Elevated levels of ferritin and hs-CRP in type 2 diabetes. J Pak Med Assoc. 64:1389–1391. 2014.PubMed/NCBI
19	Bosques CJ and Manning AM: Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs. Autoimmun Rev. 15:1081–1088. 2016. View Article : Google Scholar : PubMed/NCBI
20	Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, et al: Mineralocorticoid Receptor Antagonist Tolerability Study - Diabetic Nephropathy (ARTS-DN) Study Group: Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA. 314:884–894. 2015. View Article : Google Scholar : PubMed/NCBI
21	Liu ZQ, Li QZ and Qin GJ: Effect of Astragalus injection onplatelet function and plasma endothelin in patients with earlystage diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He ZaZhi. 21:274–276. 2001.(In Chinese).
22	Ford ES: Urinary albumin-creatinine ratio, estimated glomerular filtration rate, and all-cause mortality among US adults with obstructive lung function. Chest. 147:56–67. 2015. View Article : Google Scholar : PubMed/NCBI
23	Meneses MJ, Silva BM, Sousa M, Sá R, Oliveira PF and Alves MG: Antidiabetic drugs: Mechanisms of action and potential outcomes on cellular metabolism. Curr Pharm Des. 21:3606–3620. 2015. View Article : Google Scholar : PubMed/NCBI